|
TANAKA Norina
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Assistant Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. |
| Journal | Formal name：Experimental hematology Abbreviation：Exp Hematol ISSN code：18732399/0301472X |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | pp.in press |
| Author and coauthor | Kinoshita Ryosuke†, Ishibashi Mariko, Handa Hiroshi, Sasaki Makoto, Imai Yoichi, Tanaka Norina, Ito Shigeki, Sunakawa-Kii Mika, Kaito Yuta, Asayama Toshio, Komatsu Norio, Tanaka Junji, Odajima Takeshi, Sugimori Hiroki, Yamaguchi Hiroki, Inokuchi Koiti, Tamura Hideto |
| Publication date | 2023/02 |
| Summary | We previously showed that cell-surface CD86 expressed on multiple myeloma (MM) cells contributed to not only tumor growth but also antitumor cytotoxic T-lymphocyte responses mediated by induction of IL-10-producing CD4+ T cells. The soluble form of CD86 (sCD86) was also detected in serum from patients with MM. Thus, to determine whether sCD86 levels are a useful prognostic factor, we investigated the association of serum sCD86 levels with disease progression and prognosis in 103 newly diagnosed patients with MM. Serum sCD86 was detected in 71% of the patients with MM but was only rarely detected in patients with monoclonal gammopathy of undetermined significance and healthy controls, and the level was significantly increased in patients with advanced-stage MM. When we examined differences in clinical characteristics according to the level of serum sCD86, those in the high (≥2.18 ng/mL, n = 38) group exhibited more aggressive clinical characteristics, with shorter overall survival times compared with those in the low (<2.18 ng/mL, n = 65) group. On the other hand, it was difficult to stratify the patients with MM into different risk groups based on the expression levels of cell-surface CD86. The levels of serum sCD86 were significantly correlated with the expression levels of the messenger RNA (mRNA) transcripts of CD86 variant 3, which lack exon 6, resulting in a truncated transmembrane region, and its variant transcripts were upregulated in the high group. Thus, our findings suggest that sCD86 can be easily measured in peripheral blood samples and is a useful prognostic marker in patients with MM. |
| DOI | 10.1016/j.exphem.2023.01.006 |
| PMID | 36796620 |